{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nIn glioma cells, miR-3116-1 has been identified as a key microRNA that modulates chemoresistance to temozolomide (TMZ). Reduced levels of this miRNA in resistant glioma samples are associated with enhanced tumor cell viability, decreased apoptosis, and increased colony formation, highlighting its potential role as a sensitizer to TMZ therapy."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nMechanistic investigations revealed that miR-3116-1 directly targets the mRNA encoding fibroblast growth factor receptor 1 (FGFR1). Upregulation of miR-3116-1 leads to the downregulation of FGFR1, which in turn results in the inactivation of the PI3K/AKT signaling pathway—a critical pathway implicated in cell survival and chemoresistance. Conversely, overexpression of FGFR1 mitigates the sensitizing effects of miR-3116-1, thereby reinforcing TMZ resistance."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nThese findings underscore the therapeutic potential of modulating miR-3116-1 levels in glioma treatment. By enhancing miR-3116-1 expression, it may be possible to overcome TMZ resistance through the dual regulation of FGFR1 expression and PI3K/AKT pathway activity, providing a promising strategy for improving outcomes in glioma patients."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Shiqi Kong, Yingxiao Cao, Xin Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Mol Med (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/jcmm.15133"}], "href": "https://doi.org/10.1111/jcmm.15133"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32181582"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32181582"}]}]}]}